Cargando…

Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody

BACKGROUND: Inetetamab is a novel recombinant humanized anti-HER2 monoclonal antibody. This study aimed to evaluate the efficacy and safety of inetetamab and predictive factors for response in HER2-positive metastatic breast cancer (MBC) patients. METHODS: A cohort of HER2-positive MBC patients who...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Binliang, Xie, Ning, Tian, Can, Feng, Ronghua, Hu, Zhe-Yu, Li, Jing, Liu, Liping, Xiao, Huawu, Yang, Xiaohong, Zeng, Mengsi, Wu, Hui, Lu, Jun, Gao, Jianxiang, Hu, Xuming, Cao, Min, Shui, Zhengrong, Tang, Yu, Wu, Tao, Ouyang, Quchang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654023/ https://www.ncbi.nlm.nih.gov/pubmed/37944341 http://dx.doi.org/10.1016/j.breast.2023.103597

Ejemplares similares

FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients
por: Xie, Ning, et al.
Publicado: (2020)

Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance
por: Hu, Zhe-Yu, et al.
Publicado: (2018)

Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC
por: Tang, Yu, et al.
Publicado: (2022)

Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma
por: Cui, Jinfang, et al.
Publicado: (2023)

Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
por: Deng, Lan, et al.
Publicado: (2023)

Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial
por: Hu, Zhe-Yu, et al.
Publicado: (2023)

Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report
por: Xie, Ning, et al.
Publicado: (2021)

Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Subtyping of metastatic breast cancer based on plasma circulating tumor DNA alterations: An observational, multicentre platform study
por: Hu, Zhe-Yu, et al.
Publicado: (2022)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Impact of surgical management of primary tumors in stage IV breast cancer patients: a retrospective observational study based on SEER database
por: Xie, Ning, et al.
Publicado: (2022)

HER2-positive double primary tumor of gastric and breast cancer occur synchronously in a patient: A case report
por: OUYANG, QUCHANG, et al.
Publicado: (2016)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

PIK3CA gene mutations in the helical domain correlate with high tumor mutation burden and poor prognosis in metastatic breast carcinomas with late-line therapies
por: Tang, Yu, et al.
Publicado: (2020)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

The prognosis and risk factors for capecitabine maintenance treatment in metastatic breast cancer: a retrospective comparative cohort study
por: Tian, Can, et al.
Publicado: (2022)

Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer
por: Zhou, Dabo, et al.
Publicado: (2019)

Germline PALB2 Mutations in Cancers and Its Distinction From Somatic PALB2 Mutations in Breast Cancers
por: Hu, Zhe-Yu, et al.
Publicado: (2020)

Corrigendum to “Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer” [Translational Oncology (2019) 12, 764–774]
por: Zhou, Dabo, et al.
Publicado: (2021)

Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial
por: Cao, Jun, et al.
Publicado: (2023)

Artificial intelligence scale-invariant feature transform algorithm-based system to improve the calculation accuracy of Ki-67 index in invasive breast cancer: a multicenter retrospective study
por: Xie, Ning, et al.
Publicado: (2022)

Development of monoclonal antibodies and serological assays specific for Barley yellow dwarf virus GAV strain
por: Li, Na, et al.
Publicado: (2015)

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
por: Yu, Shengnan, et al.
Publicado: (2017)

Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients
por: Liu, Jingyu, et al.
Publicado: (2019)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

Inetetamab in combination with rapamycin and chemotherapy for trastuzumab‐treated metastatic human epidermal growth factor receptor 2‐positive breast cancer with abnormal activation of PI3K/Akt/mTOR pathway
por: Wang, Aijuan, et al.
Publicado: (2023)

A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2− metastatic breast cancer
por: Li, Yi, et al.
Publicado: (2021)

Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data
por: Anwar, Munawar, et al.
Publicado: (2021)

Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study
por: Li, Junjie, et al.
Publicado: (2018)

Epitope Mapping of Human HER2 Specific Mouse Monoclonal Antibodies Using Recombinant Extracellular Subdomains
por: Ghatar, Reza Hosseini, et al.
Publicado: (2017)

Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
por: Chen, Qitong, et al.
Publicado: (2020)

Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
por: Chen, Qitong, et al.
Publicado: (2021)

Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53-Aberrant Triple-Negative Breast Cancer
por: Hu, Zhe-Yu, et al.
Publicado: (2022)

Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
por: Xu, Yingying, et al.
Publicado: (2021)

Development and use of three monoclonal antibodies for the detection of rice black-streaked dwarf virus in field plants and planthopper vectors
por: Wu, Jianxiang, et al.
Publicado: (2013)

Monoclonal antibody-based serological methods for detection of Cucumber green mottle mosaic virus
por: Shang, Haili, et al.
Publicado: (2011)

Neddylation of HER2 Inhibits its Protein Degradation and promotes Breast Cancer Progression
por: Xia, Xiaohong, et al.
Publicado: (2023)

HER2 Is Frequently Over‐expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab
por: Fujimura, Masaki, et al.
Publicado: (2002)

Bioactivity of recombinant humanized monoclonal antibody against HER2 in-vivo and in-vitro and its mechanism of action in ovarian cancer
por: Zeng, Jinfeng, et al.
Publicado: (2023)

Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
por: Im, Seock-Ah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s8ok39uv07ov6t57h1vavj637n